H.C. Wainwright analyst Vernon Bernardino raised his price target for vTv Therapeutics to $6 from $5 after the company announced positive results from part two of its Phase 2 Simplici-T1 trial to evaluate TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes. The trial successfully achieved its primary objective of evaluating the effect of TTP399 on hemoglobin A1c, the biomarker considered the gold standard for assessing treatments for diabetes, Bernardino tells investors in a research note. He's positive on the results and reiterates a Buy rating on vTv Therapeutics. He believes the results "strongly position" vTv for partnership discussions with a diabetes-focused major pharmaceutical company that could result in "lucrative" upfront, milestone and TPP399 sales-associated royalty patients.